Video

Dr. Hurvitz on Unmet Needs in HER2+ Breast Cancer

Sara A. Hurvitz, MD, discusses unmet needs within the field of HER2-positive breast cancer.

Sara A. Hurvitz, MD, director of Breast Cancer Clinical Research Program and co-director of the Santa Monica University of California Los Angeles (UCLA) Outpatient Hematology/Oncology Practice; and an assistant professor of medicine in the Division of Hematology/Oncology of the David Geffen School of Medicine at UCLA, discusses unmet needs within the field of HER2-positive breast cancer.

Although outcomes for patients with breast cancer have improved in recent years, with disease-free survival increasing to a much higher rate, even for patients who are identified as having higher-risk HER2-positive early stage disease, unmet needs remain, says Hurvitz. Patients will sometimes have a tumor recur only in the central nervous system (CNS) because most of the therapies that are being used, with the exception of neratinib (Nerlynx), do not penetrate the blood–brain barrier. Therefore, a metastatic recurrence can be seen exclusively in the brain, sparing the rest of the body and extracranial systems, explains Hurvitz.

Ongoing studies are examining whether the incidence of metastatic recurrences in the brain can be reduced. Moreover, data from the phase 3 ExteNET study with neratinib, as well as neratinib in the metastatic setting, show that the agent successfully delays the time to a CNS metastatic recurrence, notes Hurvitz. Newer drugs, such as tucatinib (Tukysa)-based therapies, are being explored in the adjuvant setting to determine whether the incidence of CNS metastases can be reduced in this patient population. That is a huge area of unmet need right now, concludes Hurvitz.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity